23 July 2013 in Cardiology in the Young
Background: In some inherited connective tissue diseases with involvement of the cardiovascular system, for example, Marfan syndrome, early impairment of left ventricular function, which have been described as Marfan-related cardiomyopathy has been reported. Our aim was to evaluate the left ventricular function in young adults with mitral valve prolapse without significant mitral regurgitation using two-dimensional strain imaging and to determine the possible role of the transforming growth factor-β pathway in its deterioration. Methods: We studied 78 young adults with mitral valve prolapse without mitral regurgitation in comparison with 80 sex-matched and age-matched healthy individuals. Longitudinal strain and strain rates were defined using spackle tracking. Concentrations of transforming growth factor-β1 and β2 in serum were determined by enzyme-linked immunosorbent assays. Results: In 29 patients, classic relapse was identified with a leaflet thickness of ≥ 5 mm; 49 patients had a non-classic mitral valve prolapse. Despite the similar global systolic function, a significant reduction in global strain was found in the classic group (−15.5 ± 2.9%) compared with the non-classic group (−18.7 ± 3.8; p = 0.0002) and the control group (−19.6 ± 3.4%; p < 0.0001). In young adults with non-classic prolapse, a reduction in longitudinal deformation was detected only in septal segments. Transforming growth factor-β1 and β2 serum levels were elevated in patients with classic prolapse as compared with the control group and the non-classic mitral valve prolapse group. Conclusions: These changes in the deformations may be the first signs of deterioration of the left ventricular function and the existence of primary cardiomyopathy in young adults with mitral valve prolapse, which may be caused by increased transforming growth factor-β signalling.
31 October 2015 in Bulletin of Experimental Biology and Medicine
21 May 2020 in Russian journal of hematology and transfusiology
Introduction. Eculizumab inhibits the terminal steps of complement activation and is the standard treatment for paroxysmal nocturnal hemoglobinuria (PNH). Unstable complement inhibition causes “breakthrough” intravascular hemolysis and a suboptimal response to eculizumab therapy in some patients with PNH.Aim: to evaluate the stability of complement inhibition in eculizumab treatment by testing the kinetic parameters of complement activation.Materials and methods. The study included 12 PNH patients receiving long-term eculizumab therapy (median 54 months, range 4–66 months). The median age was 35 years (from 22 to 68 years), 92 % of patients were female. The median PNH clone size was 96 % of the granulocytes. The control group consisted of 12 healthy donors (age 25–60 years, women 75 %). Complement activation was evaluated immediately prior to the next eculizumab infusion, and then again after 5 and 10 days. Kinetic parameters (induction period, hemolysis rate, T50-the time required to achieve 50 % hemolysis) were recorded separately for the total complement activity and an alternative activation pathway using rabbit red blood cells (rRBC).Results. The parameters of complement activation directly before the next eculizumab administration corresponded to a marked inhibition of the overall activity of the system. The induction period was extended by 7 times compared to the control (median 180 vs 25 seconds, p < 0.0001), and the hemolysis rate was 28 times less (median 1.6 vs 45.1 × 106 rRBC/min, p < 0.0001). The T50 value exceeded the control value by 20 times (median 690 vs 35 seconds, p < 0.0001). The parameters of the alternative complement activation pathway were reduced by 2–3 times compared to the control. In one case, repeated tests revealed insuffi cient complement inhibition, which was associated with pharmacokinetic “breakthrough” hemolysis. The degree of further complement inhibition and the tendency to restore activity varied signifi cantly during dynamic testing on days 5 and 10 after eculizumab infusion.Conclusion. The results of this study demonstrate individual differences in the residual activity of complement in PNH patients receiving long-term eculizumab therapy. Testing of complement activity is necessary with a suboptimal response to eculizumab therapy and when considering therapy correction. Kinetic registration of residual complement-dependent lysis of rabbit red blood cells demonstrates a higher sensitivity than the traditional CH50 study.Conflict of interest: the authors declare no conflict of interest.Financial disclosure: the study had no sponsorship.
6 April 2020 in Regional blood circulation and microcirculation
Введение. Ключевым моментом кардиоренальных взаимоотношений является активация ренин-ангиотензин-альдостеронововй системы (РААС) и формирование дисфункции эндотелия. Цель исследования – оценить состояние эндотелийзависимой вазодилатации (ЭЗВД) при I стадии хронической болезни почек (ХБП) в зависимости от величины скорости клубочковой фильтрации (СКФ). Материалы и методы. Было обследовано 40 здоровых лиц (средний возраст – 39,2±2,0 года) и 72 больных с I стадией ХБП (средний возраст – 42,5±11,9 года). СКФ рассчитывали по формуле CKDEPI. Тканевую перфузию исследовали методом высокочастотной ультразвуковой допплерографии. Реактивность сосудов кожи оценивали в функциональных пробах с ионофорезом ацетилхолина. Результаты. По сравнению со здоровыми лицами, прирост объемной скорости кровотока на 2-й минуте пробы с ацетилхолином был снижен только при величине СКФ 90–109 мл/мин/1,73м2, при больших значениях СКФ изменений показателя не выявили. Также только у этих пациентов отмечались наиболее значимые нарушения оксидативного статуса в виде повышения концентрации в сыворотке крови диеновых конъюгатов, снижения концентрации токоферола и общих SH групп. Выводы. Нарушение эндотелийзависимой вазодилатации в пробе с ацетилхолином у больных с I стадией ХБП установлено при величине СКФ менее 109 мл/мин/1,73 м2. Нарушение показателей оксидативного статуса отмечено при величине СКФ менее 109 мл/мин/1,73 м2.